News

Filter

Current filters:

RegeneronOphthalmics

1 to 9 of 23 results

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Regeneron/Bayer Eylea filed for marketing authorization in Japan for macular edema

Regeneron/Bayer Eylea filed for marketing authorization in Japan for macular edema

04-09-2014

American biotech company Regeneron's global development partner for Eylea (aflibercept), Germany's Bayer…

BayerBiotechnologyCentral retinal vein occlusionEyleaJapanMacular degenerationMacular edemaOphthalmicsOphthalmologyRegeneronRegulationVision

Eylea approved for diabetic macular edema in Europe

Eylea approved for diabetic macular edema in Europe

11-08-2014

The European Commission has approved German pharma major Bayer’s Eylea (aflibercept) injection for…

BayerEuropeEyleaOphthalmicsOphthalmologyPharmaceuticalRegeneronRegulation

Eylea drives Regeneron’s 2nd-qtr to beat expectations

Eylea drives Regeneron’s 2nd-qtr to beat expectations

05-08-2014

USA-based biotech company Regeneron (Nasdaq: REGN) revealed today that total revenues for the second…

BiotechnologyBusiness FinanceEyleaFinancialOphthalmicsRegeneronUSA

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

Sustained improvement in vision among two-year results from Phase III Eylea trial

Sustained improvement in vision among two-year results from Phase III Eylea trial

18-07-2014

US-based biotech company Regeneron has said its Phase III trials of Eylea (aflibercept) injection for…

afliberceptBayerBiotechnologyDiabetic retinopathyEyleaLaser coagulationMacular edemaOphthalmicsRegeneronResearchUSA

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

Bayer files for EMA approval of Eylea for macular edema secondary to BRVO

11-06-2014

German pharma major Bayer has submitted an application to the European Medicines Agency seeking marketing…

BayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulation

1 to 9 of 23 results

COMPANY SPOTLIGHT

Menarini

Back to top